Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Jun 29, 2015

166_ip_2015-06-29_3878fef3-9b60-447d-80bc-40031eff1a65.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

A Leading Global Health Care Group

Roadshow BeneluxJune 29/30, 2015

For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Strong and Balanced Health Care Portfolio

Dialysis products and services

Ownership: 31% Ownership: 100% Ownership: 100% Ownership: 77%

Hospital supplies Hospital operations Hospital projects and services

i
b
i
2
0
1
4
G
N
I
C
t
t
t
r
o
u
p
e
n
c
o
m
e
o
n
r
u
o
n
2
2
%		 3
%
4		 3
%
7		 3
%

Corporate: -5%

Roadshow Benelux, Fresenius SE & Co. KGaA, Investor Relations © Copyright, June 29/30, 2015

Fresenius Medical Care: Global Market Leader in Dialysis

    • Provide highest standard of care globally to more than 286,000 patients; delivering ~43 million treatments p.a.
    • High quality dialysis products & services
  • -Complete therapy offerings
  • -Vertically integrated
    • Service portfolio expansion in the field of Care Coordination
    • Global clinic acquisitions and expansion into new geographies to support future growth

2014 Sales: US\$15,832 m; EBIT: US\$2,255 m

Fresenius Kabi: A Worldwide Leading Hospital Supplier

    • Comprehensive product portfolio for critically and chronically ill patients:
  • -IV Drugs
  • -Clinical Nutrition
  • -Infusion Therapy
  • -Medical Devices / Transfusion Technology
    • Leading market positions; global market: >€29 bn1
    • Focus on organic growth driven by geographic product rollout and robust pipeline plus selective acquisitions

Addressable market

2014 Sales: €5,146 m; EBIT: €873 m

Fresenius Helios: Leading Private Hospital Operator in Germany

  • Acute and post-acute care in 111 proprietary hospitals1
  • High-quality medical care (e.g. mortality rate for heart failure and pneumonia >30% below German average)
  • Strong track record in hospital operations and acquisitions: targeting 12 − 15% EBIT margin within 6 years per individual clinic location
  • Landmark acquisition of 41 hospitals from Rhön-Klinikum provides excellent long-term growth opportunities

As of December 31, 2014

2014 Sales: €5,244 m; EBIT: €553 m

Fresenius Vamed: A Leading Global Specialist in Hospital Projects and Services

  • Specialized in project development building hospital infrastructure and providing hospital services (technical services and operational management)
  • Track record:

    • 710 health care projects in 77 countries successfully completed

    • Services provided to 510 hospitals and 130,000 beds globally
  • Continuous demand for hospital infrastructure and operating efficiency; key markets Europe, Asia-Pacific, Africa

2014 Sales: €1,042 m; EBIT: €59 m

Fresenius Group: Sales and Net Income Reach All-Time Highs

Before special items

Fresenius Group: Dividend Development and Total Shareholder Return

Total Return: Fresenius outperforms index

Dec 31, 2004 − Dec 31, 2014

1 Proposal Source: Bloomberg; dividends reinvested 1993-2013 stock split-adjusted; 2013 pre split: €1.25

Fresenius Group: Confirming 2017 Target / Exceeding Target at Current FX Rates

~€30 billion Sales; €1.4 to €1.5 billion Net Income

Roadshow Benelux, Fresenius SE & Co. KGaA, Investor Relations © Copyright, June 29/30, 2015

Financials Q1/15

Fresenius Group: Q1/15 Financial Results

l
S
a
e
s		 1
E
B
I
T		 1
i
N
t
e
n
c
o
m
e
Q
/
1
1
5		 €
6
8
3
4
m
,		 €
8
5
1
m		 €
2
9
2
m
G
h
t
t
t
t
o
o
n
n
r
w
a
c
s
a
t
e
n
e
c
u
r
r
c
y
r
a
s		 3
%
1		 8
1
%		 1
6
%
G
h
l
t
t
t
o
a
a
c
a
r
w
u
t
c
e
n
c
a
e
s
u
r
r
y
r		 2
4
%		 3
2
%		 2
8
%

Before special items

Fresenius Group: Financial Results by Business Segment

Q
/
1
1
5		 i
F
e
s
e
n
s
r
u
d
i
l
C
M
e
c
a
a
e
r		 i
F
e
s
e
n
s
r
u
l
i
H
e
o
s		 i
F
e
s
e
n
s
r
u
d
V
a
m
e
l
S
a
e
s
h
G
t
o
r
w		 \$
3
9
6
0
U
S
m
,
1
1
%		 €
3
9
1
4
m
,
%
1
5		 €
3
9
1
1
m
,
3
%
1		 €
2
0
8
m
9
%
E
B
I
T
h
G
t
o
r
w		 \$
U
S
5
0
4
m
1
3
%		 €
2
5
7
m
2
8
%		 €
1
4
7
m
2
9
%		 €
7
m
1
%
7

Q1 Business Segment Update

Strong start into fiscal year 2015

Regional development

North America

  • -IV drug shortages easing more slowly than expected
  • Product launches ahead of schedule
  • -Expected 2015 organic sales growth range now 0% to 5%

Europe

  • Strong organic sales growth in IV drugs (10%) and Clinical Nutrition (8%)
    • Sale of €77 m German oncology compounding activities to streamline business, effective February 1, 2015

Emerging Markets

-China standing out with 12% organic sales growth

Kabi efficiency program

€100 m implementation costs confirmed for 2015; €10 m booked in Q1, remainder backloaded

Q1 Business Segment Update

Hospital business fully on track

  • Continued successful integration of acquired Rhön hospitals; amount and timing of synergy target fully confirmed
  • All labor agreements in line with budget assumptions for 2015 and 2016
  • Acquisition of 66-bed hospital, affiliated to mid-sized HELIOS Hildesheim hospital, consolidation as of April 1, 2015, annual sales of ~€8 m

Service business driving organic sales growth

  • +10% organic sales growth in service business, project business flat
  • Excellent order intake of €192 m in Q1/15 (Q1/14: €115 m)
  • On track to meet full-year guidance

Fresenius Group: Increased Outlook for Fresenius Kabi

O
l
d		 N
e
w
i
F
e
s
e
n
s
r
u
b
i
K
a		 S
l
h
t
i
a
e
s
g
r
o
w
o
r
g
a
n
c
h
E
B
I
T
t
t
t
g
r
o
w
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 3
%
%
5
–
4
%
6
%
–		 %
%
4
7
–
1
1
%
1
4
%
–
i
F
r
e
s
e
n
u
s
l
i
H
e
o
s		 l
h
S
t
i
a
e
s
g
o
r
w
o
r
g
a
n
c
S
l
h
t
d
t
a
e
s
g
r
o
w
e
p
o
e
r
r
E
B
I
T		 3
%
5
%
–
6
%
9
%
–
€
6
3
0
6
5
0
m
–
i
F
e
s
e
n
s
r
u
d
V
a
m
e		 l
h
S
t
i
a
e
s
g
r
o
w
o
g
a
n
c
r
h
E
B
I
T
t
g
o
r
w		 l
d
i
i
i
%
t
s
n
g
e
g
–
5
%
1
0
%
–

Fresenius Group: Increased Earnings Guidance

O
l
d		 N
e
w
h
R
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 7
%
1
0
%
‒
1
h
i
N
t
t
e
n
c
o
m
e
g
o
r
w
t
t
t
a
o
n
s
a
n
e
n
c
c
u
r
r
c
y		 9
%
2
%
1
‒		 3
%
6
%
1
1
–

1 Net income attributable to shareholders of Fresenius SE& Co.KGaA; 2015 before integration costs for hospitals of Rhön-Klinikum AG (~€10 m before tax), before costs for efficiency program at Fresenius Kabi (~€100 m before tax) and disposal gains from the divestment of two HELIOS hospitals (€34 m before tax); 2014 before special items

Attachments

Fresenius Group: Profit and Loss Statement

€
m		 Q
/
Q
/
1
1
5
1
1
4		 G
h
Q
t
o
r
w		 /
1
1
5
Y
Y
o
t
t
c
o
n
s
a
n
t
a
e
s
r		 l
t
a
c
a
u
t
a
e
s
r
S
l
a
e
s		 6
8
3
4
,		 2
2
5
1
,		 3
%
1		 2
%
4
1
E
B
I
T		 8
5
1		 6
4
3		 1
8
%		 3
2
%
N
i
t
t
t
e
n
e
e
s
r		 6
1
5
-		 3
8
1
-		 %
7
-		 2
0
%
-
I
t
n
c
o
m
e
a
e
s
x		 2
0
7
-		 1
3
3
-		 3
8
%
-		 5
6
%
-
2
N
i
t
e
n
c
o
m
e		 2
9
2		 2
2
8		 6
%
1		 2
8
%

1 2015 before integration costs for acquired Rhön hospitals (€2 m), before costs for efficiency program at Fresenius Kabi (€10 m) and disposal gains from the divestment of two HELIOS hospitals (€34 m); 2014 before Fenwal integration costs (€1 m) and disposal gains from the divestment of two HELIOS hospitals (€22 m)

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs for acquired Rhön hospitals (€2 m), before costs for efficiency program at Fresenius Kabi (€7 m) and disposal gains from the divestment of two HELIOS hospitals (€34 m); 2014 before Fenwal integration costs (€1 m) and disposal gains from the divestment of two HELIOS hospitals (€21 m)

Roadshow Benelux, Fresenius SE & Co. KGaA, Investor Relations © Copyright, June 29/30, 2015

Fresenius Kabi: Strong Organic Sales Growth

€
m		 Q
/
1
1
5		 Q
/
1
1
4		 O
i
a
r
g
n
c
h
G
t
r
o
w
I.
V
D
r
u
g
s		 5
4
5		 4
4
1		 6
%
l
l
C
i
i
N
i
i
t
t
n
c
a
u
r
o
n		 3
7
2		 3
1
8		 9
%
f
h
I
i
T
n
u
s
o
n
e
r
a
p
y		 2
3
1		 2
3
0		 0
%
d
l
/
M
i
D
i
e
e
e
c
a
v
c
s
f
h
l
T
i
T
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 2
6
4		 2
2
4		 0
%
l
l
T
t
o
a
s
a
e
s		 3
9
1
4
,		 2
3
1
1
,		 %
5

Fresenius Kabi: Strong EBIT Growth in all regions

€
m		 /
Q
1
1
5		 /
Q
1
1
4		 h
G
t
r
o
w
E
o
p
e
u
r
M
i
a
g
n
r		 8
3
1
6.
0
%		 6
9
1
3.
8
%		 2
0
%
h
N
A
i
t
o
m
e
c
a
r
r
M
i
g
n
a
r		 1
7
6
3
7.
2
%		 1
4
7
3
8.
5
%		 2
0
%
f
f
/
/
A
i
P
i
i
L
i
A
i
A
i
t
n
m
e
s
a
a
c
c
a
r
c
a
r
c
a
-
M
i
a
r
g
n		 6
3
6
%
1
5.		 9
4
8
%
1
4		 2
9
%
d
C
C
R
&
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 6
5
-		 6
4
-		 2
%
-
l
T
E
B
I
T
t
o
a
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 2
5
7		 2
0
1		 2
8
%
0
%
1
i
M
a
r
g
n		 8
1
5
%		 1
6
6
%

EBIT excluding costs for Fresenius Kabi's efficiency program (€10 m)

Fresenius Helios: Sales Growth in Line with Expectations

€
m		 /
Q
1
1
5		 /
Q
1
1
4		 h
G
t
r
o
w
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o		 2
6
3
1
,		 2
1
1
4
,		 %
4
A
i
i
i
t
q
s
o
n
s
(
l
d
)
c
u
i
i
1
t
<
c
o
n
s
o
a
o
n
y
r		 1
2
8
i
i
D
t
t
e
s
e
s
(
d
l
d
)
v
u
r
i
t
i
1
<
e
c
o
n
s
o
a
o
n
y
r		 1
3
l
l
T
t
o
a
a
e
s
s		 3
9
1
1
,		 2
2
1
7
,		 3
%
1

Fresenius Helios: Strong EBIT margin increase of established clinic portfolio

€
m		 Q
/
1
1
5		 Q
/
1
1
4		 G
h
t
r
o
w
l
l
T
t
o
a
s
a
e
s		 1
3
9
1
,		 1
2
2
7
,		 1
3
%
E
B
I
T
f
b
l
h
d
l
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
o
o
r
M
i
a
r
g
n		 1
4
3
1
1.
3
%		 1
1
3
9
3
%		 2
7
%
/
A
i
i
i
D
i
i
t
t
t
c
q
s
o
n
s
e
s
e
s
u
v
u
r
(
l
i
d
i
/
d
l
i
d
i
1
)
t
t
<
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
y
r		 4 1
l
T
t
E
B
I
T
o
a		 1
4
7		 1
1
4		 2
9
%
i
M
a
g
n
r		 1
0
6
%		 9
3
%

EBIT excluding disposal gains from the divestment of two HELIOS hospitals (€34 m) and integration costs for acquired Rhön hospitals (€2 m)

Fresenius Helios: Performance Indicators

/
Q
1
1
5		 /
Q
1
1
4		 h
C
a
n
g
e
1
f
h
l
N
i
t
o
o
o
s
p
a
s
l
A
i
i
t
e
a
e
n
s
c
u
c
r
c
c
-
P
l
i
i
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 1
1
1
8
7
2
4		 0
1
1
8
6
2
4		 0
%
0
%
0
%
1
f
b
d
N
o
o
e
s
l
A
i
i
t
e
e
n
c
u
c
a
r
c
c
s
-
P
l
i
i
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 3
2
0
2
4
,
2
9,
0
2
9
5,
1
7
3		 3
8
8
4
1
,
2
9,
0
6
8
5,
1
2
0		 0
%
0
%
1
%
d
A
i
i
m
s
s
o
n
s
(
)
A
i
i
t
t
t
e
e
n
p
e
n
c
u
c
a
r
a
-		 3
0
5,
9
0
5		 2
7
6,
6
0
0		 1
1
%
O
p
a
n
c
c
u
c
y
P
t-
t
o
e
e
s
a
c
u
c
a
r
-		 7
8
%		 7
9
%
f
l
h
(
d
)
A
t
t
e
a
g
e
e
n
g
o
s
a
a
s
v
r
y
y
2
A
t
e
e
c
u
c
a
r
-
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 6.
6
2
6.
8		 6.
6
2
7.
1

1December 31, 2014

2German average (2013): 7.5

Fresenius Helios: 2014 Clinic Development Plan

i
f
l
i
Y
P
t
e
a
s
n
o
o
o
r
r
1
<		 1 2 3 1
4		 5 6 6
>		 1
l
T
t
o
a
f
l
N
i
i
o.
o
c
n
c
s		 - - 2
1		 3 0
4		 - 6 9
4		 1
1
1
(
€
)
R
e
v
e
n
u
e
m		 - - 0
4
1		 6
0
1		 9
9
1,
7		 - 2
0
5		 2,
5
1
5		 0
8
0
5,
T
t
a
r
g
e
(
%
)
E
B
I
T
i
m
a
r
g
n		 - 2.
0		 0
4		 6.
0		 8.
0		 0.
0
1		 2.
0
1		 2.
0-
0
1
1
5.
(
)
E
B
I
T
€
m		 - - 1
6.
0		 9
6		 1
4
3.
9		 - 2
4
6		 8
3
0
1.		 4
9
5.
9
d
R
t
e
p
o
r
e
(
%
)
E
B
I
T
i
m
a
r
g
n		 - - 8.
1		 8
4		 9
7.		 - 8.
8		 3.
1
5		 0.
6
1
(
)
E
B
I
T
€
m		 - - 3
2.
4		 7.
7		 1
4
1.
2		 - 8.
1
0		 8.
3
3
3		 5
3
7.
6
f
l
N
i
i
t
t
>
o.
o
c
n
c
s
a
r
g
e		 - - 8 1 9
1		 - 2 2
2		 2
5
f
l
N
i
i
t
t
<
o.
o
c
n
c
s
a
r
g
e		 - - 4 2 2
1		 - 4 2
7		 8
5

1 includes all hospitals acquired from Rhön Klinikum, €29 m integration costs allocated to individual hospitals.

Roadshow Benelux, Fresenius SE & Co. KGaA, Investor Relations © Copyright, June 29/30, 2015

Fresenius Vamed: Strong Order Intake

€
m		 Q
/
1
1
5		 Q
/
1
1
4		 G
h
t
o
r
w
b
P
j
i
t
r
o
e
c
u
s
n
e
s
s		 8
0		 8
0		 0
%
b
S
i
i
e
c
e
s
n
e
s
s
r
v
u		 1
2
8		 1
1
1		 1
5
%
l
l
T
t
o
e
a
s
a
s		 2
0
8		 9
1
1		 9
%
l
T
t
E
B
I
T
o
a		 7 6 1
7
%
i
M
a
g
n
r		 3
4
%		 3
1
%
1
d
i
k
O
t
r
e
r
n
a
e		 1
9
2		 1
1
5		 6
7
%
1
d
b
k
l
O
r
e
r
a
c
o
g		 1
5
1
0
,		 2
1
3
9
8
,		 8
%

Project business only

2December 31, 2014

Fresenius Group: Leverage Ratio

Net debt/EBITDA (at annual average FX rates for both EBITDA and net debt)

Pro forma acquisitions; before special items

2Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG; before special items

3Before special items; without major acquisitions

Fresenius Group: Consistent Cash Generation and Proven Track Record of Deleveraging

Cash Flow Development LTM

€
m		 O
p
e
r
a		 i
(
)
h
l
C
F
C
F
C
F
t
t
n
g
a
p
e
x
n
e
r
e
e
a
s
o		 1
w
Q
/
L
T
M
1
1
5		 i
L
T
M
M
a
r
g
n		 Q
/
L
T
M
1
1
5		 i
L
T
M
M
a
r
g
n		 Q
/
L
T
M
1
1
5		 i
L
T
M
M
a
r
g
n
8
6
2		 8
1
2
%		 3
5
2
-		 6
6
%
-		 3
3
0		 6
2
%
5
9
5		 1
1
0
%		 2
6
2
-		 4
8
%
-		 3
3
3		 3
6
2
%
8 8
0
%		 9
-		 0
9
%
-		 1
-		 0
1
%
-
Co
/
te
rp
or
a
O
he
t
r		 2
5
-		 n
a		 7
-		 n
a		 3
2
-		 n
a
l.
F
M
C
ex
c		 1
2
6
0
,		 2
1
1
4
%		 6
3
0
-		 5
4
%
-		 6
3
0		 2
6
0
%
G
ro
up		 2
9
6
7
,		 2
%
1
1		 3
3
1
5
-
,		 %
5
5
-		 6
2
3
1
,		 6
6
%

1 Before acquisitions and dividends

2 Margin incl. FMC dividend

3 Understated: 7.4% excluding €69 m of capex commitments from acquisitions

Margin = in % of sales

Roadshow Benelux, Fresenius SE & Co. KGaA, Investor Relations © Copyright, June 29/30, 2015

Share Information

Share key facts

Number of shares1 542,815,402 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Depositary bank Deutsche Bank

Ratio 4 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Exchange OTCQX International Premier Structure Sponsored Level I ADR

As of March 31, 2015

Financial Calendar 2015

30.07.2015 Report on 2nd quarter 2015

29.10.2015 Report on 3rd quarter 2015

Please note that these dates could be subject to change.

Contact

k
G
M
i
a
r
u
s
e
o
r
g		 S
l
V
P
I
R
i
t
t
n
v
e
s
o
r
e
a
o
n
s
S
&
C
G
F
i
E
K
A
r
e
s
e
n
u
s
o
a		 l
l
L
i
I
t
e
s
e
g
e
n		 l
V
P
I
R
i
t
t
n
v
e
s
o
r
e
a
o
n
s
S
&
C
G
F
i
E
K
A
r
e
s
e
n
u
s
o
a
h
p
o
n
e
:
l
i
e
-m
a
:		 9
6
2
6
0
8
2
8
4
1
7
4
5
+
-
k
f
M
G
i
@
i
a
s.
e
o
g
e
s
e
n
s.
c
o
m
r
u
r
r
u		 h
p
o
n
e
:
l
i
e
-m
a
:		 9
6
2
6
0
8
8
4
1
7
4
4
7
+
-
l
l
f
L
i
I
@
i
t
e
s
e
g
e
n
e
s
e
n
s.
c
o
m
r
u

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.